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ABSTRACT: Sharbat-e-Unsul, a Unani medicine was found to cure zeequn – nafasbalghami or 
“difficulty in breathing due to narrowing or obstruction of air passage”.  The drug did not cause 
any adverse effect. 
 
INTRODUCTION 
 
Even after tremendous advancements in 
medical science ZEEQUN  –  NAFAS 
(asthma) still remains a problem to the 
clinicians.  In spite of continuous efforts and 
long list of known anti asthmatic drugs, 
physicians are unable to find out permanent 
cure. 
 
The word ZEEQUN-NAFAS is comprises 
of two Arabic words.  ZEEQ  and NAFAS, 
means “narrowing” and “breathing” 
respectively.  In other words, it is defined as 
difficulty in breathing due to narrowing or 
obstruction of air passage, particularly in 
expiration (1,2). 
 
In Unani system of medicine different types 
of ZEEQUN-NAFAS have been described 
and are based on their causative factors, for 
example, if it is caused by cessation of 
phlegmatic humours (thick sticky sputum) in 
tracho – bronchial tree, known as ZEEQUN 
–  NAFAS BALGHAMI or  NAZLI 
(Phlegamtic asthma); if caused by 
Tazhannuj-e-shobatur Ria (Narrowing of 
Bronchial tree), known as ZEEQUN-
NAFAS SHOABI   or  ASBI  (Bronchial 
asthma); is caused by congestion of fluid in 
respiratory tract due to other disorders, like 
heart (Qalb), known as ZEEQUN NAFAS 
SHIRKI.  The first and second types are 
very common in India due to air pollution 
and last two due to poor hygienic conditions 
resulting from low body resistance (3, 4, 5). 
 
ZEEQUN NAFAS BALGHAMI affects 
men and women in all ages.  This is an 
unpredictable and long term diseases.  There 
are various factors in the environment and 
the body of individual itself which provoke 
the diseases.  According to Unani medical 
theory, it mainly predisposes in those 
individuals having phlegmatic temperament.  
The treatment of the disease based on 
NUZUJ  (Cocotion),  TAFTEESH-
UROOQE-KHASHINA  
(Bronchodialation) and TANFEES 
(Expectoration) (6,7). 
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TABLE – 1 
 
Shows the age and sex medicine 
 
Age Group  Percentage  Sex 
Male (%)  Female (%) 
 
31 to 40 
 
41 to 50 
 
51 to 60 
 
61 to 70 
 
 
26.7 
 
20.6 
 
26.7 
 
26.6 
 
26.7 
 
20.0 
 
13.3 
 
26.7 
 
- 
 
- 
 
13.3 
 
- 
 
 
There are a large numbers of single and 
polypharmaceutical Ayurvedic, Unani and 
Allopathic preparations which are useful in 
this diseases.  A Unani preparation 
SHARBAT-E-UNSUL  (Syrup of Urginea 
indica)  which possesses anti-asthmatic 
effect by dialating the trachea-bronchial tree 
and expelling out the phlegm.  Regarding 
the usefulness of Unsul,  Abu  Bakar 
Mohammad bin Zakaria Razi (841 –  923 
AD), an eminent Arab Physician said, “it is 
an effective and potent drug for ZEEQUN-
NAFAS-BALGHAMI  and acts by 
expelling out the phlegmatic homours of the 
lungs” (8,9). 
 
MATERIALS AND METHODS 
 
The study was conducted at Ajmal Khan 
Tibbiya College Hospital Aligarh Muslim 
University, Aligarh on 36 patients.  The 
following exclusive and inclusive criteria 
was adopted for the selection of patients. 
 
TABLE 2 
 
Shows the history of previous illness 
 
 
Disease 
 
 
Percentage 
 
Pneumonia 
 
Chronic Bronchitis 
 
Rhinitis 
 
Allergy 
 
 
26.7 
 
26.7 
 
33.3 
 
13.3 Pages 12 - 15 
 
TABLE 3 
 
Shows the temperament of the patients  
 
 
Temperament 
 
 
Percentage 
 
Sanguinic (Damvi) 
 
Phelgmatic (Balghami) 
 
Choleric (Safravi) 
 
Melencholic (Saudavi) 
 
 
6.6 
 
73.4 
 
20.0 
 
- 
 
 
Patients having acute and chronic stage of 
paroxysm of dysponea with or without 
cough, expectoration and wheezing.  They 
were not less than 20 years of age, of both 
sexes and were not suffering from any other 
systematic disease causing breathlessness.  
The diagnosis was made on complete 
clinical history including temperamental, 
physical, and systematic examinations along 
with haematological, radiological and 
routine laboratory tests.  Pulmonary function 
test was also conducted before and at the 
end of the study. 
 
TABLE 4 
 
Shows the stages of symptoms before treatment 
 
Symptoms  Server (%)  Moderate (%)  Mild (%) 
Breathlessness 
 
Cough 
 
Expectoration 
86.7 
 
60.0 
 
- 
13.3 
 
40.0 
 
20.0 
- 
 
- 
 
80.0 
 
 
 
SHARBAT—E-UNSUL was prepared in 
sugar-based syrup and was given in the dose 
of 10 ml 12 hourly (morning and evening) 
up to 4 weeks orally (10). 
 
Observation and Results 
 
It is observed at the end of the study that the 
age incidence of the patients was 26.7% in 
31  –  40 years, 20.0% in 41 –  50 years, 
26.7% in 51- 60 years, and 26.6% in 61-70 
years of age group respectively.  In the sex 
incidence, male patients were 26.7% in 31 – 
40 years, 20% in 41-50 years, 13.4% in 51-Pages 12 - 15 
60 years, and 26.0% in 61-70 years of age 
group while female patients were 13.3% in 
51-60% years of age group only (Table 1).  
These results reveal that male are more 
prone than female. 
 
TABLE 5 
 
Shows percentage relief in symptoms after treatment 
 
Symptoms  Complete Relief  Moderate Relief  Partial Relief  No Relief 
 
Breathlessness 
 
Cough 
 
Expectoration 
 
26.70 
 
23.32 
 
15.00 
 
35.00 
 
46.70 
 
35.35 
 
30.00 
 
28.32 
 
65.51 
 
 
8.35 
 
1.65 
 
- 
 
According to the history of previous illness.  
The pneumonic patients were 26.7%, 
chronic Bronchial diseased 26.7%, Rhinitic 
33.3% and allergic 13.3% (Table 2).  The 
temperamental study showed 6.6% DAMVI 
(Sanguinic), 73.4% BALGHAMI 
(Phegmatic) 20% SAFRAVI (Choleric) and 
no patient was recorded SAUDAVI 
(melancholic) temperament (Table 3).  It 
showed that the majority of the patients had 
phlegmatic temperament. 
 
TABLE – 7 
 
Pulmonary function test before and after treatment 
 
Group  Before 
Treatment 
(%) 
After 
Treatment 
(%) 
Vital Capacity Test (V. C.): 
 
2000 to 2500 ml 
 
3001 to 3500 ml 
 
3501 to 4000 ml 
 
Forced Expiratory Time 
Test (F.E.T) 
 
Forced Expiratory 
 
Time Test (F.E.T) 
 
 
 
73.4 
 
13.3 
 
13.3 
 
 
 
 
 
 
 
 
 
 
21.6 
 
16.7 
 
61.7 
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3 to 4 Seconds 
 
5 to 6 Seconds 
 
7 to 8 Seconds 
13.4 
 
80.0 
 
6.6 
68.4 
 
28.3 
 
3.3 
 
 
 
According to the stages and degree of 
symptoms before treatment, severe 
breathless was 86.7%, moderate 
breathlessness was 13.3% and no any case 
was mild stage.  In relation to severity of 
cough 60% (severe), 40 (moderate) and non 
of mild stage were observed patients had 
moderate (20%), mild (80%) and no any 
case of severe expectoration.  In relation to 
improvement and relief after treatment 
complete 26.70%, moderate 35%, partial 
30% and no relief 8.35% was recorded.  In 
relation to cough, complete (23.32%), 
moderate (46.70%), mild (28.32%) and no 
relief (1.65%) respectively and in relation to 
expectoration 15%, 35.35%, 65.5% of 
severe, moderate and mild relief respectively 
was found (Table 5).  The relief in rhonchi 
before treatment recorded as general 46.7% 
zonal 53.3%.  After treatment, rhonchi 
remained as general 5%, zonal (23.3%), 
partial ( 58.3%) of cases and in 13.3% of 
cases rhonchi disappeared (Table 6).  In 
pulmonary function tests was 73.4% in 
2000ml – 2500 ml group, 13.3% in 3001 – 
3500 ml. group , 13.3% in 3501 – 4000 ml. 
group and after completion of treatment and 
was 21.6% in 2000 ml – 2500 ml. group, 
16.7% 3001 ml. –  3500 ml. group 61.7% 
2501 ml –  4000 ml. group and FET test 
(Forced expiratory time) at the beginning of 
the study in the group 3 – 4 seconds, 13.4%, 
in 5 – 6 seconds, 80% and in 7 – 8 seconds, 
6.6% while at the end of the study it is 
recorded as 68.4%, 28.3%, 3.3% 
respectively (Table 7). 
 
CONCLUSION  
 
The overall percentage of relief in symptoms 
and sign after four weeks of study was 
91.75% in breathlessness, 98.35% in cough, 
85.00 in expectoration and 86.7% in 
wrhonci.  It reveals that Sharabat-e-Unsul 
is an effective drug for ZEEQUN-NAFAS-
BALGHMI,  which clears the passage by 
dialating the trachea-bronchial leumen and 
expelling out the phlegmatic homous from 
the lung.  It reduces the intensity of the 
symptoms like breathlessness and cough and 
sign like wrhonchi and wheez, and increases 
expectoration.  It does not show any adverse 
effects in this study. 
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